A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a ...

Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in ...

TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.

Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...

On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” ...

In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

The “Great Healthcare Plan” is vague, but would send money directly to ACA enrollees and entrench the pricing deals the ...

More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene ...

Raw materials play a critical role in cell therapy manufacturing. Choosing suboptimal materials at any stage of development ...